At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 35 enrolled
Drug / intervention
Bevacizumab +2 moredrug
Likely dose
Not stated in record
Key inclusion· 3
- ✓Histologically proven intracranial glioblastoma multiforme with pathologic or imaging confirmation of tumor progression or regrowth after failure of two previous treatment regimens
- ✓Initial low-grade glioma that progressed to glioblastoma or gliosarcoma
- ✓History and physical exam, including neurologic examination, within 4 weeks prior to registration
Key exclusion· 1
- ✕Active bleeding or pathological condition carrying high risk of bleeding in patients on warfarin or low-molecular-weight heparin
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prospective Study of Stereotactic Radiosurgery Using Diffusion-Weighted Abnormality Versus Chemotherapy for Recurrent/Progressive Glioblastoma After Second-line Chemotherapy
In Brief
A Phase 3 clinical trial evaluating Bevacizumab, Chemotherapy, and 1 other intervention for Recurrent or Progressive Glioblastoma. Completed, enrolled 35 participants across 1 site.
Detailed Summary
This clinical trial is a prospective study of radiosurgery treatment for progressive GBM to test 1)the efficacy of radiosurgery for recurrent/progressive GBM compared to chemotherapy , and 2) the role of diffusion-weighted image (DWI) to predict the early tumor progression and treatment response.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent or Progressive Glioblastoma
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2010
Primary CompletionDec 2016
First PostedFeb 2023
TodayJul 2026
First PostedFeb 8, 2023
Enrollment StartNov 1, 2010
Primary CompletionDec 1, 2016
TodayJul 2, 2026
Enrollment to primary: 6.1 yearsPosted 3.4 years ago
Interventions
Bevacizumabdrug
Chemotherapydrug
Fractionated radiosurgeryradiation